Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France
2024; Elsevier BV; Volume: 12; Issue: 10 Linguagem: Inglês
10.1016/s2213-8587(24)00241-9
ISSN2213-8595
AutoresMehdi Maanaoui, Rémi Lenain, Yohann Foucher, Fanny Buron, Gilles Blancho, Corinne Antoine, Sophie Caillard, L. Kessler, Moglie Le Quintrec, Orianne Villard, Dany Anglicheau, Matthias Büchler, Albane Brodin-Sartorius, Luc Frimat, Paolo Malvezzi, Sandrine Lablanche, Lionel Badet, Laure Esposito, Mikaël Chetboun, Aghilès Hamroun, Julie Kerr‐Conte, Thierry Berney, Marie‐Christine Vantyghem, Marc Hazzan, François Pattou,
Tópico(s)Cannabis and Cannabinoid Research
ResumoIslet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to assess the effect of islet transplantation on patient-graft survival in kidney transplant recipients with type 1 diabetes.
Referência(s)